The FDA Opened the Door to an Experimental Pancreatic Cancer Drug. Who Gets to Walk Through It?

On April 30, 2026, the FDA issued a "safe to proceed" letter allowing expanded access to daraxonrasib, an oral drug made by Revolution Medicines that targets a genetic defect present in roughly 90% of pancreatic cancers [1]. The agency acted just two days after receiving the application — an unusual pace that FDA Commissioner Marty Makary called a reflection of "the FDA's strong commitment to facilitate early access to therapies for serious and life-threatening conditions" [2]. The decision followed Phase 3 trial data showing daraxonrasib nearly doubled median overall survival compared with standard chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) [3].

The move comes at a time when pancreatic cancer remains one of the deadliest malignancies in the United States. Approximately 60,000 Americans are diagnosed each year, and half present with metastatic disease [4]. The five-year survival rate hovers around 12%, and for metastatic patients it is far lower. For decades, the KRAS oncogene — mutated in roughly 90–92% of pancreatic tumors — was considered "undruggable" [5]. Daraxonrasib is the first RAS inhibitor to demonstrate an overall survival benefit in this population, a fact that has drawn comparisons to the introduction of imatinib (Gleevec) for chronic myeloid leukemia.

But expanded access is not approval. The drug has not completed the regulatory process, its price has not been announced, and the history of early-access oncology drugs includes a substantial rate of ultimate failure. The question now is not only whether daraxonrasib works — the trial data suggest it does — but who will be able to get it, under what conditions, and what happens if confirmatory trials fall short.

The Trial Data: What Justified the Decision

The pivotal evidence comes from the RASolute 302 trial, a global, open-label, randomized Phase 3 study comparing daraxonrasib to standard-of-care chemotherapy in patients with previously treated metastatic PDAC [3].

The headline number: median overall survival of 13.2 months for daraxonrasib versus 6.7 months for chemotherapy — a roughly 97% improvement and a statistically significant reduction in the risk of death of approximately 60% [3][6]. The drug also showed statistically significant improvements in progression-free survival.

Source: Revolution Medicines / RASolute 302 Trial

Data as of Apr 14, 2026CSV

To put these figures in context, the standard second-line chemotherapy options for metastatic pancreatic cancer — typically FOLFIRINOX (a combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin) or gemcitabine-based regimens — have historically offered median overall survival of roughly 5 to 7 months in pretreated patients [7]. An improvement of 6.5 months in median survival is substantial by the standards of pancreatic oncology, where gains are typically measured in weeks.

The trial enrolled patients with KRAS G12 mutations, which account for the vast majority of KRAS-mutant pancreatic tumors. KRAS G12D is the most common subtype at roughly 40%, followed by G12V at 29% and G12R at 15% [4][5]. This means most pancreatic cancer patients would, in principle, be eligible based on biomarker criteria.

Revolution Medicines presented updated Phase 1/2 data at the 2026 American Association for Cancer Research (AACR) Annual Meeting, including first-line treatment results showing daraxonrasib monotherapy produced grade 3 or higher treatment-related adverse events in 38% of patients, compared with 73% for chemotherapy [8]. Full RASolute 302 results are scheduled for presentation at the ASCO Annual Meeting in Chicago, May 29 to June 2, 2026 [9].

How Daraxonrasib Works — and Why It Took So Long

KRAS mutations have been known to drive pancreatic cancer since the 1980s. For nearly four decades, the protein's smooth, pocket-free surface frustrated drug designers who could find no place for a small molecule to bind [5]. The first breakthrough came with sotorasib and adagrasib, which targeted the relatively rare KRAS G12C variant (about 1% of pancreatic cancers). Daraxonrasib represents a broader advance: it is a RAS(ON) multi-selective inhibitor, meaning it can block multiple active KRAS variants simultaneously — including G12D, G12V, and G12R, which together comprise the vast majority of pancreatic KRAS mutations [10].

The drug is taken orally, once daily, which distinguishes it from the intravenous chemotherapy regimens that have been the backbone of pancreatic cancer treatment. This oral delivery route has practical implications for patients: it eliminates the need for infusion center visits and the complications associated with intravenous access.

The scientific interest in KRAS-targeted therapy has surged in recent years. According to OpenAlex data, publications on "KRAS pancreatic cancer" grew from 769 in 2011 to a peak of 9,012 in 2023, reflecting both the growing recognition of KRAS as a central driver and the emergence of druggable approaches [11].

Source: OpenAlex

Data as of Jan 1, 2026CSV

The Safety Profile: Manageable but Not Benign

Daraxonrasib's side effects are distinct from those of cytotoxic chemotherapy. In the RASolute 302 trial, any-grade treatment-related adverse events occurred in 98% of patients in the dosing group, with grade 3 or higher events in 29–34% [8][12]. The most common were:

• Rash: 91% any grade, 8% grade 3 or higher
• Diarrhea: 48% any grade, 2% grade 3 or higher
• Nausea: 43% any grade
• Vomiting: 31% any grade
• Stomatitis (mouth sores): 31% any grade, 3% grade 3 or higher
• Fatigue: 20% any grade

Treatment-related adverse events led to dose interruptions in 34% of patients and dose reductions in 19%. No patients discontinued treatment due to adverse events [12].

These numbers compare favorably to chemotherapy, where grade 3 or higher events were reported in 73% of patients receiving standard-of-care in the first-line setting [8]. The rash — the most common daraxonrasib side effect — is a class effect of RAS pathway inhibitors and is generally managed with dose adjustments and supportive medications.

The FDA's expanded access authorization will require monitoring and adverse event reporting, though specific risk evaluation and mitigation strategy (REMS) details have not been publicly disclosed [1][2].

The Regulatory Pathway: Expanded Access, Not Approval

The FDA's decision uses the expanded access (sometimes called "compassionate use") pathway, which is distinct from both accelerated approval and full approval [1]. Under expanded access, the drug remains investigational. Patients who have no other treatment options and who meet clinical criteria can receive the drug outside of a clinical trial, but the manufacturer must still complete the regulatory approval process.

Daraxonrasib has also received Breakthrough Therapy Designation and Orphan Drug Designation from the FDA, as well as a non-transferable voucher under the Commissioner's National Priority Voucher pilot program, awarded in October 2025 [13][14]. These designations expedite the review process but do not lower the evidentiary bar for eventual approval.

The expanded access pathway is not the same as accelerated approval, which allows drugs to be marketed based on surrogate endpoints before confirmatory trials are complete. The historical record for accelerated approval in oncology offers a cautionary data point: among 46 cancer drugs granted accelerated approval between 2013 and 2023 with more than five years of follow-up, only 43% confirmed clinical benefit in subsequent trials, 35% did not demonstrate benefit, and 22% were withdrawn [15][16].

Source: OncLive / Drug Topics

Data as of Aug 1, 2024CSV

As of August 2024, 30 cancer drug indications — 18% of all accelerated approvals granted between 1992 and 2022 — had been withdrawn [15]. Notable withdrawals include bevacizumab for breast cancer, gefitinib for non-small cell lung cancer (later reapproved for a biomarker-selected population), and several checkpoint inhibitor indications [17]. From approval to withdrawal, more than one-quarter of eligible patients had started therapy on drugs that were later pulled from the market [17].

Daraxonrasib's expanded access pathway differs from these examples in a key respect: it does not confer marketing authorization, so the drug cannot be commercially promoted, and Revolution Medicines must supply it to participating sites under the expanded access protocol. This limits the scale of patient exposure relative to accelerated approval but also restricts access to sites that are set up to participate.

Who Makes the Drug, Who Funded the Science

Revolution Medicines, a publicly traded biotech company headquartered in San Francisco (NASDAQ: RVMD), developed daraxonrasib [13]. The company has raised substantial capital to fund its RAS-focused pipeline. In April 2026, Revolution Medicines priced a public offering of 10.56 million shares at $142 each, raising approximately $1.5 billion [18]. The company also has a $2 billion funding agreement with Royalty Pharma, comprising up to $1.25 billion in synthetic royalty payments and up to $750 million in corporate debt [19]. Under a separate agreement, Royalty Pharma will pay Revolution Medicines $250 million contingent on a positive data readout from RASolute 302 before January 1, 2028 [19].

The extent of public funding that contributed to daraxonrasib's development is less transparent. The foundational science on KRAS biology and druggability drew on decades of NIH-funded research across multiple academic institutions, though specific grant amounts flowing into daraxonrasib's development have not been publicly itemized by Revolution Medicines [5][10]. This is a recurring pattern in pharmaceutical development: public funding supports the basic science, private capital funds clinical development, and the financial arrangements between the two are often opaque.

The Case for Caution

The strongest argument against expanded access before full approval is not that daraxonrasib doesn't work — the RASolute 302 data are robust by pancreatic cancer standards — but that premature adoption of experimental therapies has a documented track record of unintended consequences.

First, early access can slow enrollment in the very confirmatory trials needed to secure full approval. If patients can get the drug outside a trial, some may decline randomization, particularly to a control arm. This effect has been observed with other expanded access programs and can delay the generation of definitive evidence [16][20].

Second, the historical record shows that early confidence in oncology drugs is not always borne out. Gefitinib's initial accelerated approval for unselected lung cancer patients, based on response rate data, was followed by five failed confirmatory trials before the drug was eventually approved for a narrower, biomarker-defined population [17]. The lesson: strong Phase 3 data reduces but does not eliminate the risk that broader use will reveal limitations invisible in a trial population.

Third, expanded access is not equitable access. Patients must be treated at sites participating in the protocol, which in practice means academic medical centers and large cancer networks. Patients at community hospitals — where the majority of cancer care in the United States is delivered — are far less likely to have access [21][22]. Fewer than 5% of cancer patients globally participate in clinical trials, and the barriers that drive that low number — geography, insurance, race, socioeconomic status — apply equally to expanded access programs [22].

The Equity Gap

Pancreatic cancer disparities are well documented. Black patients are 19% more likely to be diagnosed with late-stage disease and 25% less likely to undergo surgical resection than white patients [23]. A study using the California Cancer Registry found that Black patients were 34% less likely to undergo surgery for resectable disease compared with white patients [23]. These disparities appear to be driven primarily by social determinants — insurance status, proximity to high-volume treatment centers, referral patterns — rather than biological differences. After adjusting for socioeconomic factors, race did not independently affect survival in at least one large Veterans Affairs study [24].

Expanded access programs, by their design, tend to amplify rather than reduce these disparities. Participation requires a treating oncologist who is aware of the program, willing to navigate the administrative requirements, and affiliated with a site that can meet the FDA's monitoring and reporting obligations. Patients in rural areas, those with Medicaid or no insurance, and those receiving care at low-volume community hospitals are structurally disadvantaged [21][22][23].

Revolution Medicines' expanded access protocol does not, based on publicly available information, include specific provisions to address geographic or socioeconomic equity [13]. The Pancreatic Cancer Action Network and other advocacy organizations have called for expanded access programs to include site diversity requirements and patient navigation support, but these are recommendations, not requirements [7].

The Confirmatory Trial Timeline

Revolution Medicines has already begun enrolling patients in RASolute 303, a Phase 3 trial evaluating daraxonrasib as a first-line treatment for metastatic pancreatic cancer. Patient dosing began as of April 2, 2026 [25]. The trial is randomized, open-label, and global, comparing daraxonrasib monotherapy and daraxonrasib plus gemcitabine/nab-paclitaxel against standard chemotherapy. Primary endpoints are progression-free survival and overall survival [25].

A separate trial, RASolute 304, is evaluating daraxonrasib in resectable PDAC following adjuvant chemotherapy, and enrolled its first patient in early 2026 [26].

These trials are funded by Revolution Medicines. The company reported spending $660 million on research and development in 2025 and has indicated that its recent capital raises — the $1.5 billion equity offering and the $2 billion Royalty Pharma agreement — are intended to fund the RAS pipeline through potential commercialization [18][19].

If the confirmatory trials fail to meet their endpoints, patients already receiving daraxonrasib through the expanded access program would face an uncertain situation. Under FDA regulations, sponsors can continue providing drug through expanded access even after a negative trial result, but they are not required to do so. Revolution Medicines has not publicly addressed this contingency [1][13].

What Comes Next

The ASCO presentation at the end of May 2026 will provide the first full public look at the RASolute 302 data, including subgroup analyses, quality-of-life measures, and mature survival curves [9]. Revolution Medicines is expected to file for FDA approval based on these data, with the Breakthrough Therapy and National Priority Voucher designations potentially accelerating the review timeline.

If approved, daraxonrasib's pricing will become the next focal point. The drug's cost has not been disclosed, but oral oncology drugs in the targeted therapy class typically cost $10,000 to $20,000 per month at U.S. list prices. For comparison, FOLFIRINOX chemotherapy costs approximately $2,000 to $4,000 per cycle, though it requires infusion center visits and carries higher rates of severe side effects [7].

For the roughly 30,000 Americans diagnosed each year with metastatic pancreatic cancer who carry KRAS mutations, daraxonrasib represents the first targeted therapy to show a survival benefit [3][4][5]. Whether the promise of expanded access translates into equitable access — across race, geography, insurance status, and hospital type — remains an open question that the current regulatory framework does not answer.